Detalhe da pesquisa
1.
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
Nature
; 604(7907): 749-756, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35444283
2.
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.
Res Sq
; 2024 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38410486
3.
PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.
Mol Cancer Ther
; 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38781103
4.
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
J Med Chem
; 65(15): 10251-10284, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35880755
5.
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.
Mol Cancer Ther
; 21(2): 245-256, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34911817
6.
The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer.
Nat Cancer
; 2(12): 1357-1371, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35121901